Insulin ludefen
Tracked across 1 events · 8 articles · First seen Jun 12, 2026 · Last active Jun 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Insulin ludefen, an ultra-long-acting once-weekly basal insulin analog developed by Gan & Lee Pharmaceuticals, met its primary endpoint in the SUPER-3 Phase III clinical trial in China, demonstrating superior HbA1c reduction and a favorable safety profile.
Jun 12, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Insulin ludefen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard